Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MPC2 | O95563 | 2/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832961 | 0.89 | PPARG (0.68) | PPARGLMNAMAPK1CASP3SENP7 | |
| SCHEMBL936979 | 0.82 | PPARG (0.79) | PPARGLMNAMAPK1CASP3SENP7 | |
| SCHEMBL24212244 | 0.81 | PPARG (0.71) | PPARGLMNAMAPK1L3MBTL1MPC2 | |
| SCHEMBL8282082 | 0.79 | LMNA (0.53) | PPARGLMNAMAPK1CASP3SENP7 | |
| SCHEMBL25832955 | 0.78 | PPARG (0.49) | PPARGMPC2CYP2C8CYP2C9TP53 | |
| SCHEMBL8176942 | 0.76 | HTT (0.51) | PPARGLMNAPOLBTP53HSD17B10 | |
| SCHEMBL6327817 | 0.74 | LMNA (0.73) | LMNAMAPK1CASP3SENP7SENP6 | |
| SCHEMBL23946231 | 0.73 | LMNA (0.52) | PPARGLMNAMAPK1CASP3SENP7 | |
| SCHEMBL15811630 | 0.71 | PPARG (0.81) | PPARGMPC2CYP2C8CYP2C9TP53 | |
| SCHEMBL19217836 | 0.70 | PPARG (0.87) | PPARGMPC2CYP2C8CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | CIRIUS THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | ACE, DPP4, ACE2 | PPARG 19/4885LMNA 616/4885MAPK1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.